NO329695B1 - Anvendelse av syklisk RGD pentapeptid antagonist til αv integriner - Google Patents

Anvendelse av syklisk RGD pentapeptid antagonist til αv integriner Download PDF

Info

Publication number
NO329695B1
NO329695B1 NO20013750A NO20013750A NO329695B1 NO 329695 B1 NO329695 B1 NO 329695B1 NO 20013750 A NO20013750 A NO 20013750A NO 20013750 A NO20013750 A NO 20013750A NO 329695 B1 NO329695 B1 NO 329695B1
Authority
NO
Norway
Prior art keywords
cells
tumor
brain
cell
vitronectin
Prior art date
Application number
NO20013750A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013750D0 (no
NO20013750L (no
Inventor
Walter E Laug
Original Assignee
Los Angeles Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26815994&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO329695(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Los Angeles Childrens Hospital filed Critical Los Angeles Childrens Hospital
Publication of NO20013750D0 publication Critical patent/NO20013750D0/no
Publication of NO20013750L publication Critical patent/NO20013750L/no
Publication of NO329695B1 publication Critical patent/NO329695B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20013750A 1999-02-01 2001-07-31 Anvendelse av syklisk RGD pentapeptid antagonist til αv integriner NO329695B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11812699P 1999-02-01 1999-02-01
US09/489,391 US6521593B1 (en) 1999-02-01 2000-01-21 Methods for inhibiting brain tumor growth
PCT/US2000/001949 WO2000044404A2 (fr) 1999-02-01 2000-01-26 Procedes d'inhibition de la croissance de tumeurs cerebrales

Publications (3)

Publication Number Publication Date
NO20013750D0 NO20013750D0 (no) 2001-07-31
NO20013750L NO20013750L (no) 2001-09-28
NO329695B1 true NO329695B1 (no) 2010-12-06

Family

ID=26815994

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013750A NO329695B1 (no) 1999-02-01 2001-07-31 Anvendelse av syklisk RGD pentapeptid antagonist til αv integriner

Country Status (21)

Country Link
US (2) US6521593B1 (fr)
EP (1) EP1150714B1 (fr)
JP (1) JP4708568B2 (fr)
KR (1) KR100704139B1 (fr)
CN (2) CN1191858C (fr)
AT (1) ATE395934T1 (fr)
AU (2) AU775064B2 (fr)
BR (1) BR0007875A (fr)
CA (1) CA2360146C (fr)
CZ (1) CZ301480B6 (fr)
DE (1) DE60038951D1 (fr)
DK (1) DK1150714T3 (fr)
ES (1) ES2304942T3 (fr)
HU (1) HU230025B1 (fr)
MX (1) MXPA01007765A (fr)
NO (1) NO329695B1 (fr)
PL (1) PL202082B1 (fr)
PT (1) PT1150714E (fr)
RU (1) RU2377017C2 (fr)
SK (1) SK287326B6 (fr)
WO (1) WO2000044404A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2333845T3 (es) * 1999-01-06 2010-03-02 University Of Southern California Metodo y composicion para la inhibicion de la angiogenesis.
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7829087B2 (en) 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
EP1414491A4 (fr) * 2001-07-09 2005-07-06 Elan Pharm Inc Procedes inhibant la toxicite amyloide
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20070185077A1 (en) * 2003-07-15 2007-08-09 Washington University Methods of treating, preventing and inhibiting cancer metastasis and tumor formation
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
CA2539288C (fr) 2003-09-15 2015-05-12 Shaker A. Mousa Analogues d'hormone thyroidienne et methodes d'utilisation associees
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
ITRM20040105A1 (it) * 2004-02-27 2004-05-27 Tecnogen Scpa Anticorpo monoclonale antitenascina umana.
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US9220788B2 (en) * 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20090022806A1 (en) * 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
WO2007035612A2 (fr) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Composes de liaison rgd et leurs procedes d'utilisation
US20090035312A1 (en) * 2005-09-30 2009-02-05 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP2054442A2 (fr) * 2006-06-14 2009-05-06 Cell-Matrix, Inc. Peptides de collagène dénaturés et leurs utilisations
EP2064244B1 (fr) 2006-08-03 2019-06-05 MedImmune Limited ANTICORPS DIRIGÉS CONTRE alphaVbeta6 ET LEURS UTILISATIONS
EP2120913B1 (fr) * 2006-12-22 2015-01-21 NanoPharmaceuticals LLC Formulations de nanoparticules et de polymères pour les analogues, les antagonistes et les formulations de l'hormone thyroïde et leurs utilisations
US20110243927A1 (en) * 2007-08-24 2011-10-06 University Health Network Methods of inhibiting tumor growth using beta 5 integrin antagonists
EP2706358A3 (fr) 2008-12-23 2014-05-07 Merck Patent GmbH Biomarqueurs pour inhibiteurs présentant une activité anti-angiogénique
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
US9180107B2 (en) * 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
CN101659694B (zh) * 2009-05-06 2012-12-12 河北科技大学 抗肿瘤环五肽化合物及其制备方法
CA2810746A1 (fr) 2010-06-30 2012-01-05 Galderma Research & Development Procede de prevention ou de traitement des tumeurs cutanees
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
CN102145161A (zh) * 2011-04-07 2011-08-10 中国药科大学 整合素阻断剂在制备治疗肿瘤药物中的应用
CA2856329A1 (fr) 2011-11-17 2013-05-23 Glia Sp Z.O.O. Compositions et methodes de traitement du gliome
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
US20170000905A1 (en) * 2015-06-30 2017-01-05 Mousera, Inc Device and method of personalized medicine
US10201616B2 (en) 2016-06-07 2019-02-12 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
WO2020030954A1 (fr) 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Protéines sanp de type théragnostique conjuguées à des peptides de ciblage de l'intégrine et de la pmsa et thérapie du cancer de la prostate
RU2709215C1 (ru) * 2019-09-12 2019-12-17 Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Институт катализа им. Г.К. Борескова Сибирского отделения Российской академии наук" (ИК СО РАН) Способ подавления роста опухолей глиального происхождения
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2123338C1 (ru) * 1990-06-15 1998-12-20 Сайтел Корпорейшн Фармацевтическая композиция на основе медиатора межклеточной адгезии (варианты), способ ингибирования межклеточной адгезии, способ лечения воспалительного заболевания, способ анализа тестируемого соединения на способность ингибировать клеточную адгезию, способ получения соединения
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
EP0719859B1 (fr) * 1994-12-20 2003-07-02 MERCK PATENT GmbH Anticorps monoclonal contre l'integrine alpha-V
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE19613933A1 (de) * 1996-04-06 1997-10-09 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
EP0951295B1 (fr) * 1996-05-31 2010-06-09 The Scripps Research Institute Compositions pour l'utilisation afin d'inhiber l'angiogenese mediee par alpha-v- beta3
JP2001509176A (ja) * 1997-01-17 2001-07-10 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
CZ20002269A3 (cs) * 1998-12-14 2001-01-17 Merck & Co., Inc. Látky antagonizující receptor íntegrinu

Also Published As

Publication number Publication date
PL359602A1 (en) 2004-08-23
AU2004220756B2 (en) 2007-05-10
NO20013750D0 (no) 2001-07-31
NO20013750L (no) 2001-09-28
CA2360146A1 (fr) 2000-08-03
CN1332713C (zh) 2007-08-22
CN1660426A (zh) 2005-08-31
WO2000044404A2 (fr) 2000-08-03
RU2005107614A (ru) 2006-08-27
DE60038951D1 (de) 2008-07-03
DK1150714T3 (da) 2008-08-18
CZ20012793A3 (cs) 2002-03-13
CN1191858C (zh) 2005-03-09
EP1150714B1 (fr) 2008-05-21
JP2002535375A (ja) 2002-10-22
JP4708568B2 (ja) 2011-06-22
CZ301480B6 (cs) 2010-03-17
KR20020001726A (ko) 2002-01-09
ATE395934T1 (de) 2008-06-15
US6521593B1 (en) 2003-02-18
AU775064B2 (en) 2004-07-15
PT1150714E (pt) 2008-07-30
CN1355711A (zh) 2002-06-26
EP1150714A2 (fr) 2001-11-07
PL202082B1 (pl) 2009-05-29
CA2360146C (fr) 2013-05-21
MXPA01007765A (es) 2003-06-04
ES2304942T3 (es) 2008-11-01
SK10622001A3 (sk) 2002-04-04
BR0007875A (pt) 2002-02-13
SK287326B6 (sk) 2010-07-07
US20030157098A1 (en) 2003-08-21
KR100704139B1 (ko) 2007-04-09
HUP0105155A2 (hu) 2002-04-29
AU2737900A (en) 2000-08-18
AU2004220756A1 (en) 2004-11-11
HUP0105155A3 (en) 2004-08-30
WO2000044404A3 (fr) 2000-11-30
HU230025B1 (hu) 2015-05-28
RU2377017C2 (ru) 2009-12-27

Similar Documents

Publication Publication Date Title
NO329695B1 (no) Anvendelse av syklisk RGD pentapeptid antagonist til αv integriner
MacDonald et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an αv integrin antagonist
US6475488B1 (en) Methods of inhibiting angiogenesis and ameliorating cancer by using superfibronectin
Kim et al. Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin
EP0754059B2 (fr) Compositions inhibitrices de l'angiogenese et procedes correspondants
WO1998012226A9 (fr) Procede permettant de freiner l'evolution des cancers et d'inhiber l'angiogenese a l'aide de fibronectine
EP2327451B1 (fr) Procédés de détection et d'inhibition de l'angiogénèse
US20210155696A1 (en) Enhancing the therapeutic activity of immune checkpoint inhibitor
EP3302557B1 (fr) Antagoniste du collagène pour l'augmentation de l'activité thérapeutique d'un inhibiteur de point de contrôle immunitaire dans le traitement du mélanome
Matuszewska et al. Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer
RU2255765C2 (ru) Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов
WO2018042182A1 (fr) Compositions et leurs utilisations
CA2582224A1 (fr) Compositions et methodes de modulation de la regeneration des tissus et des reponses chimiotactique
ZA200106069B (en) Methods for inhibiting brain tumor growth by using selected integrin antagonists.
US20180015144A1 (en) Agonists of the nogo-a s1pr pathway for the treatment of glioblastoma

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees